Medicine
Mavyret 100 mg/40 mg tablet
Mavyret 100 mg/40 mg tablet is a prescription medicine containing Glecaprevir and Pibrentasvir for oral use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at or below 30°C (86°F).
Key facts
- Active ingredient (INN)
- Glecaprevir and Pibrentasvir
- Brand
- Mavyret
- Strength
- 100 mg/40 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 cartons, 2 cartons, 84 tablets and 1 more
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Store at or below 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AP57 Glecaprevir and Pibrentasvir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 August 2017
- Identifiers
- RxCUI 1940703, 1940709, 2557906 +1DailyMed set ID 7bf99777-0401-9095-8645-16c6e907fcc0NDC 0074-2625Application NDA209394
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 carton in 1 carton / 7 blister pack in 1 carton / 3 tablet, film coated in 1 blister pack | 0074-2625-04 | AbbVie | 15 April 2025 |
| 4 carton in 1 carton / 7 dose pack in 1 carton / 3 tablet, film coated in 1 dose pack | 0074-2625-28 | AbbVie | 3 August 2017 |
| 2 carton in 1 carton / 4 carton in 1 carton / 7 dose pack in 1 carton / 3 tablet, film coated in 1 dose pack | 0074-2625-56 | AbbVie | 3 August 2017 |
| 84 tablet, film coated in 1 bottle | 0074-2625-84 | AbbVie | 22 June 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Glecaprevir and Pibrentasvir
Clinical summary
Glecaprevir and Pibrentasvir is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor and a hepatitis C virus NS5A inhibitor indicated for the treatment of adult, among other approved uses. MedsAcross supplies Glecaprevir and Pibrentasvir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Glecaprevir and PibrentasvirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Mavyret prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Maviret: European public assessment report (EPAR) · European Medicines Agency
Need Mavyret 100 mg/40 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.